Poster

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.

Certara2026 年 6 月 9 日

Blog

Beyond Compliance: What ICH M15 Means for the Future of Drug Development

Explore how ICH M15 is shaping regulatory expectations for Model-Informed Drug Development (MIDD), including model…

Certara2026 年 6 月 9 日

Publication

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…

Dorottya Gui-Bodnar2026 年 5 月 28 日

Publication

尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型

This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a…

Certara2026 年 5 月 21 日

On-Demand Webinar

Pharmacometrics Under Pressure Part 3: The Wall: When the Model Gets Harder Than Planned

Learn how Phoenix NLME and RsNLME support advanced PK/PD workflows and complex pharmacometric modeling through…

Certara2026 年 5 月 20 日

Webinar

Minimize risk when preparing for hepatic impairment studies

Certara2026 年 5 月 12 日

On-Demand Webinar

Pharmacometrics Under Pressure Part 2 – The Steady Miles: Project-Grade PMx Without Losing Pace

See how Phoenix NLME and RsNLME support scalable and manageable workflows as project demands evolve.

Danielle Pillsbury2026 年 5 月 8 日

Webinar

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

Certara2026 年 5 月 8 日

Blog

What We Learned at Phoenix UGM at Certainty 2026 About the Future of PK/PD

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= 2026 年 5 月 8 日 At Certainty 2026, the Phoenix User Group Meeting brought together scientists,…

Certara2026 年 5 月 8 日

Publication

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…

Certara2026 年 5 月 7 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

临床药理学

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Beyond Compliance: What ICH M15 Means for the Future of Drug Development

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型

Pharmacometrics Under Pressure Part 3: The Wall: When the Model Gets Harder Than Planned

Minimize risk when preparing for hepatic impairment studies

Pharmacometrics Under Pressure Part 2 – The Steady Miles: Project-Grade PMx Without Losing Pace

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

What We Learned at Phoenix UGM at Certainty 2026 About the Future of PK/PD

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

订阅时事通讯

快捷链接

解决方案

联系我们